Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

U.K. slaps GSK with $54.4M fine for decade-old pay-for-delay deal

The U.K.'s Competition and Markets Authority was only formed in 2014, but it didn't mind reaching back more than a decade for evidence to slap GlaxoSmithKline with a $54.4 million (£37.6 million) fine. In its first pay-for-delay decision, it said the U.K. company thwarted generic competition to its antidepressant drug Seroxat by paying off a handful of generic players.

Biogen allies with GSK in precompetitive computational biology collaboration

GlaxoSmithKline has gained an ally in its push to accelerate drug discovery by collaborating on the application of computational biology to target validation. The ally, Biogen, is the first firm to join the initiative since GSK set it up in collaboration with the Wellcome Trust Sanger Institute and the European Bioinformatics Institute in 2014.

GlaxoSmithKline signs two new vaccine R&D partnerships

GlaxoSmithKline's flu vaccines, Fluarix and FluLaval, are both egg-based and can take months to produce each year. Now, the company has signed a pair of research deals, one of which would allow it to make cell-based vaccines, which are more efficient to manufacture.

Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too

Some of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.

Biogen joins a GSK-led data-sharing project to make R&D more efficient

Biogen has signed up with a GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.

GSK's slow-off-the-blocks Anoro gets a leg up from Incruse sidekick

Not every market has been enthusiastic about slow-starting GlaxoSmithKline respiratory newcomer Anoro. But the company has been offering doctors another option, too--and it's starting to pay off.

GSK says China poised to rebound as reorganization gathers pace

GlaxoSmithKline saw another sharp drop in China sales of established pharmaceuticals, but CEO Andrew Witty said that was all part-and-parcel of reshaping the business including sales of products in the Middle Kingdom and that 2016 should start to see a turnaround, along with emerging markets generally.

GSK's vax revenues jump in 2015 while profit, margin slip

Thanks to flailing pharma revenues and its decision to ship away its oncology assets, GlaxoSmithKline has a lot riding on vaccines. And in 2015, the unit delivered with 19% revenue growth, although profit and operating margin both fell.

Hold your horses on an OTC spinoff, GSK chief tells breakup-happy analysts

GlaxoSmithKline CEO Andrew Witty is running out of ways to say it: A spinoff of the consumer health joint venture it shares with Novartis just isn't happening right now.

NCI's Cancer Centers join in HPV vaccination push

All 69 of the United States' National Cancer Institute-designated centers have joined together to issue a statement urging an increase in HPV vaccinations, declaring the vaccines "tragically underused" and calling low uptake a "public health threat."